Prostate cancer is the second most common cancer among men worldwide.
Alterations in the DNA methylation pattern can be one of the leading causes for prostate cancer formation. This study is the first high-throughput sequencing study investigating genome-wide DNA methylation patterns in a large cohort of 51 tumor and 53 benign prostate samples using methylated DNA immunoprecipitation sequencing. Comparative analyses identified more than 147,000 cancer-associated epigenetic alterations. In addition, global methylation patterns show significant differences based on the TMPRSS2-ERG rearrangement status. We propose the hypermethylation of miR-26a as an alternative pathway of ERG rearrangement-independent EZH2 activation. The observed increase in differential methylation events in fusion-negative tumors can explain the tumorigenic process in the absence of genomic rearrangements.
Written by:
Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR. Are you the author?
Department of Vertebrate Genomics and Next Generation Sequencing Group, Max Planck Institute for Molecular Genetics; Department of Biology, Chemistry, and Pharmacy, Free University, Berlin; Cancer Genome Research and Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases, Heidelberg; Cellzome AG, Heidelberg; Sividon Diagnostics GmbH, Cologne; Biotechnology Center, Technical University Dresden, Dresden; Martini Clinic, Prostate Cancer Center and Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Institute for Computational Biomedicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York; and Centre for Integrative Biology, University of Trento, Trento, Italy.
Reference: Cancer Discov. 2012 Oct 23. Epub ahead of print.
doi: 10.1158/2159-8290.CD-12-0041
PubMed Abstract
PMID: 22930729
UroToday.com Investigative Urology Section
